A large‐scale study was done by Xiaofeng et al, who not only offered a detailed overview of 92 BC CLs and their molecular classification (luminal A, luminal B, HER2‐positive and triple‐negative subtypes divided into basal A and basal B) but also highlighted inconsistencies in studies with regard to primary marker status reports.31 Here, ERBB2 is linked to breast cancer.